Furthermore, we have corroborated the correlation between PDGFRA levels and treatment response in lenvatinib-treated liver cancer patients through patient biopsy samples, proposing that the targeting of PDGFRA could represent an efficacious strategy to surmount lenvatinib resistance. The gene discussed is PDGFRA; the disease is liver cancer.